奥沙利铂联合卡培他滨化疗治疗进展期胃癌的疗效及安全性

Efficacy and Safety Analysis of Oxaliplatin Combined with Capecitabine in the Treatment for Advanced Gastric Cancer

目的:探讨奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效及安全性。方法:80例进展期胃癌患者,根据随机数字法,将其分为对照组(ECF化疗)和观察组(奥沙利铂联合卡培他滨新辅助化疗),比较两组临床疗效、毒副反应,以及1年生存率。结果:与对照组相比,观察组有效率明显升高,P<0.05;与对照组相比,观察组胃肠道反应、骨髓抑制等毒副作用发生率显著降低,P<0.05;与对照组相比,观察组1年生存率明显提高,P<0.05。结论:奥沙利铂联合卡培他滨治疗能够明显提高进展期胃癌患者治疗的临床疗效,降低化疗期间的毒副反应,提升患者的生存率。

Objective:To study the clinical efficacy and safety of oxaliplatin combined with capecitabine in the treatment for advanced gastric cancer.Methods:The 80 patients with advanced gastric cancer were randomized into the control group(ECF chemotherapy) and the observation group(oxaliplatin combined with capecitabine in the neoadjuvant chemotherapy) according to the random number method.The clinical efficacy,toxicity,and the 1-year survival rate in the two groups were compared.Results:Compared with the control group,the effective rate was significantly increased in the observation group(P<0.05);compared with the control group,the toxicity incidence of gastrointestinal reactions and bone marrow suppression were obviously reduced in the observation group(P<0.05);compared with the control group,the 1-year survival rate was significantly increased in the observation group(P<0.05).Conclusion:The treatment of oxaliplatin combined with capecitabinecan significantly the clinical efficacy for patients with advanced gastric cancer,reduce the toxicity reactions during the treatment period,and improve the patients' survival rate.